Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025

1.1 Statement of the Report
1.2 Executive Summary

3.1 Progress made in Autologous Cell Therapy using iPSCs
3.1.1 Examples of Autologous iPSC-derived Cell Therapies in Development
3.1.2 Manufacturing Timeline for Autologous iPSC-derived Cell Products
3.1.3 Cost of iPSC Production
3.1.4 Automation in iPSC Production
3.2 Allogeneic iPSC-based Cell Therapies
3.3 Share of iPSC-based Research within the Overall Stem Cell Industry
3.4 Major Focus Areas of iPSC Companies
3.5 Commercially Available iPSC-derived Cell Types
3.6 Relative use of iPSC-derived Cell Types in Toxicology Testing Assays
3.7 iPSC-derived Cell Types used in Clinical Trials
3.8 Currently Available iPSC Technologies
3.8.1 Brief Descriptions of some iPSC-related Technologies
3.8.1.1 Nucleofector Technology
3.8.1.2 Opti-ox Technology
3.8.1.3 MOGRIFY Technology
3.8.1.4 Transcription Factor-based iPSC Differentiation Technology
3.8.1.5 Flowfect Technology
3.8.1.6 Technology for Mass Production of Platelets
3.8.1.7 SynFire Technology

4.1 First iPSC Generation from Mouse Fibroblasts, 2006
4.2 First Human iPSC Generation, 2007
4.3 Creation of CiRA, 2010
4.4 First High-Throughput Screening using iPSCs, 2012
4.5 First iPSC Clinical Trial Approved in Japan, 2013
4.6 First iPSC-RPE Cell Sheet Transplantation for AMD, 2014
4.7 EBiSC Founded, 2014
4.8 First Clinical Trial using Allogeneic iPSCs for AMD, 2017
4.9 Clinical Trial for Parkinson’s Disease using Allogeneic iPSCs, 2018
4.10 Commercial iPSC Plant SMaRT Established, 2018
4.11 First iPSC Therapy Center in Japan, 2019
4.12 First U.S.-based NIH-Sponsored Clinical Trial using iPSCs, 2019
4.13 Cynata Therapeutics’ World’s Largest Phase III Clinical Trial, 2020
4.14 Tools and Know-how to Manufacture iPSCs in Clinical Trials, 2021
4.15 Production of in-house iPSCs using Peripheral Blood Cells, 2022

5.1 Rapid Growth in iPSC Publications
5.1.1 PubMd Publications on Pathophysiological Research using iPSCs
5.1.2 PubMed Papers on Reprogramming
5.1.3 PubMed Papers on iPSC Differentiation
5.1.4 PubMed Papers on the use of iPSCs in Drug Discovery
5.1.5 PubMed Papers on iPSC-based Cell Therapy
5.1.5.1 Percent Share of Published Articles by Disease Type
5.1.5.2 Percent Share of Articles by Country

6.1 iPSC Patent Applications by Jurisdiction
6.2 iPSC Patent Applicants
6.3 Inventors of iPSC Patents
6.4 iPSC Patent Owners
6.5 Legal Status of iPSC Patents

7.1 Number of iPSC Clinical Trials
7.1 Recruitment Status of iPSC Clinical Trials
7.3 iPSC Clinical Trials Stydy Designs
7.4 Therapeutic & Non-Therapeutic iPSC Clinical Trials
7.4.1 Non-Therapeutic Clinical Studies by Use
7.4.2 Diseases Targeted by Therapeutic Studies
7.4.2.1 Therapeutic Clinical Studies by Autologous & Allogeneic Sources of iPSCs 71
7.4.3 Examples of iPSC-based Therapeutic Studies
7.5 iPSC-based Trials by Phase of Study
7.6 iPSC Clinical Trials by Funder Type
7.7 Geographic Distribution of iPSC-based Clinical Trials
7.8 Promising iPSC Product Candidates
7.8.1 CYP-001, CYP-004 & CYP-006 from Cynata Therapeutics
7.8.2 BioVAT-HF from Repairon GmbH
7.8.3 HS-001 from Heartseed
7.8.4 CNTY-101 from Century Therapeutics
7.8.5 FT-576 & FT-819 from Fate Therapeutics
7.8.6 RPE from National Eye Institute
7.8.7 QN-019a from Qihan Biotech
7.8.8 iPSC-CL from Heartworks, Inc.
7.9 Companies having Preclinical iPSC Assets
7.9.1 Aspen Neuroscience
7.9.2 Ryne Biotech
7.9.2 Bluerock Therapeutics
7.9.4 Vita Therapeutics
7.9.5 Hopstem Biotechnology
7.9.6 Res Nova Bio, Inc
7.9.7 Cytovia Therapeutics
7.9.8 Hebecell Corporation
7.9.9 Sana Biotechnology
7.9.10 SCG Cell Therapy Pte
7.9.11 Cytomed
7.9.12 Shoreline Biosciences
7.9.13 Neukio Biotherapeutics
7.9.14 Exacis Biotherapeutics
7.9.15 CellOrigin Biotech

8.1 Mergers and Acquisitions (M&A) Sector
8.1.1 Century Therapeutics & Clade Therapeutics
8.1.2 Evotech & Rigenerand
8.1.3 Fujifilm Corporation & Atara Biotherapeutics
8.1.4 Catalent & RheinCell Therapeutics
8.1.5 Axol Biosciences & Censo Biotechnologies
8.1.6 Bayer AG & Bluerock Therapeutics
8.1.7 Pluriomix & Axiogenesis
8.2 Partnership/Collaboration & Licensing Deals in iPSC Sector
8.2.1 Shinobi Therapeutics & Panasonic
8.2.2 SCG Cell Therapy and A*STAR
8.2.3 Charles River Laboratories & Pluristyx, Inc
8.2.4 Pluristyx, Inc. & National Resilience, Inc.
8.2.5 University of Texas & GeneCure
8.2.6 Heartseed, Inc. & Undisclosed Biotech
8.2.7 Bluerock Therapeutics & Bit.bio
8.2.8 Applied Stem Cell, Inc. & CIRM
8.2.9 Resolution Therapeutics & OmniaBio, Inc
8.2.10 REPROCELL, Inc. & CIRM
8.2.11 REPROCELL, Inc. & BioBridge Global
8.2.12 Elevate Bio & CIRM
8.2.13 Evotec & Sernova
8.2.14 Evotec & Almiral
8.2.15 Quell Therapeutics & Cellistic
8.2.16 MDimmune & YiPSCELL
8.2.17 Edigene & Neukio Biotherapeutics
8.2.18 Matricelf & Ramot
8.2.19 Evotec & Boehringer Ingelheim
8.2.20 Pluristyx, Pancella & Implant Therapeutics
8.2.21 Century Therapeutics & Bristol Myers Squibb
8.2.22 Fujifilm Cellular Dynamics & Pheno Vista Biosciences
8.2.23 Metrion Biosciences & Bioqube Ventures
8.2.24 Cytovia Therapeutics & Cellectis
8.2.25 Exacis Biotherapeutics & CCRM
8.2.26 Cynata Therapeutics & Fujifilm Corporation
8.2.27 Bone Therapeutics & Implant Therapeutics
8.2.28 REPROCELL & TEXCELL
8.2.29 Jacobio & Herbecell
8.2.30 NeuCyte & KIF1A.ORG
8.2.31 Kite & Shoreline Biosciences
8.2.32 Neuropath Therapeutics & Hopstem Biotechnology
8.2.33 Allele Biotech & Cellatoz
8.2.34 Bluerock Therapeutics, Fujifilm Cellular Dynamics & Opsis Therapeutics
8.2.35 Newcells & Takeda
8.2.36 Biocentriq & Kytopen
8.2.37 Fujifilm Cellular Dynamics & Sana Biotechnology
8.2.38 Evotec & Medical Center Hamburg-Eppdorf (UKE)
8.2.39 NeuCyte & Seaver Autism Center for Research and Treatment
8.2.40 Cytovia Therapeutics & National Cancer Institute
8.2.41 Mogrify & MRC Laboratory of Molecular Biology
8.3 Venture Capital Funding in iPSC Sector
8.3.1 Asgard Therapeutics
8.3.2 Kenai Therapeutics
8.3.3 Pluristyx
8.3.4 Fujifilm Cellular Dynamics
8.3.5 Mogrify Ltd
8.3.6 Heartseed, Inc.
8.3.7 Elevate Bio
8.3.9 Aspen Neurosciences
8.3.10 Axol Biosciences
8.3.11 Thyas, Co. Ltd
8.3.12 Synthego
8.3.13 Cellino Biotech, Inc
8.3.14 Curi Bio
8.3.15 Ncardia
8.3.16 Evotec SE
8.3.17 bit.bio
8.3.18 Clade Therapeutics
8.3.19 Shoreline Biosciences
8.3.20 Kytopen
8.3.21 Cytovia Therapeutics & CytoLynx
8.3.22 TreeFrog Therapeutics
8.3.23 HebeCell Corporation
8.3.24 Neukio Biotherapeutics
8.3.25 Stemson Therapeutics
8.3.26 Vita Therapeutics
8.3.27 Century Therapeutics
8.3.28 Heartseed
8.3.29 Mogrify
8.3.30 Metrion Biosciences
8.3.31 Elevate Bio
8.3.32 Vita Therapeutics

9.1 OSKM Cocktail
9.1.1 Octamer-binding Transcription Factor 4 (Oct4)
9.1.2 Sry-related Box (SOX) Factor 2
9.1.3 Kruppel-like Factors (Klf4)
9.1.4 C-Myc
9.2 Pluripotency-Associated Transcription Factors and their Functions
9.2.1 Different Combinations of Factors for Different Cell Sources
9.3 Delivery of Reprogramming Factors
9.3.1 Integrating Systems
9.3.1.1 Retroviral Vectors
9.3.1.2 Lentiviral Vectors
9.3.1.3 piggyBack (PB) Transposon Method
9.3.2 Non-Integrative Delivery Systems
9.3.2.1 Adenoviral Vectors
9.3.2.2 Sendai Viral Vectors
9.3.2.3 Plasmid Vectors
9.3.2.4 Minicircles
9.3.2.5 oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1)-based Episomes
9.3.2.6 RNA Delivery Approach
9.3.2.7 Proteins
9.3.3 Comparison of Delivery Methods
9.4 Genome Editing Technologies in iPSC Generation
9.4.1 CRISPR/Cas9
9.5 Available iPSC Lines and their applications

10.1 Major Biobanks Storing iPSCs & iPSC Lines
10.1.1 RIKEN
10.1.1.1 Human iPS Cells offered by RIKEN
10.1.2 WiCell
10.1.2.1 WiCell’s iPSC Lines
10.1.3 Fujifilm Cellular Dynamics, Inc.
10.1.3.1 iPSC Generation
10.1.4 Sampled
10.1.4.1 Biobanking Services
10.1.4.2 Sampled’s iPSC Services
10.1.5 Coriell Institute for Medical Research
10.1.5.1 iPSCs at Coriell
10.1.5.2 Coriell’s Biobank
10.1.5.2.1 National Institute of General Medical Sciences (NIGMS)
10.1.5.2.2 National Institute on Aging (NIA)
10.1.5.2.3 Allen Cell Collection
10.1.5.2.4 iPSC Collection from Rett Syndrome Research Trust
10.1.5.2.5 Autism Research Resource
10.1.5.2.6 HD Community BioRepository
10.1.5.2.7 CDC Cell and DNA Repository
10.1.5.2.8 NEI-AREDS Genetic Repository
10.1.6 European Bank for Induced Pluripotent Stem Cells (EBiSC)
10.1.6.1 EBiSC Catalogue
10.1.6.2 EBiSC’s iPSC Banking Service
10.2 Cell Sources for iPSC Banks
10.3 Reprogramming Methods in iPSC Banks
10.4 Ownership and Investments made in iPSC Banks

11.1 iPSCs in Basic Research
11.1.1 To Understand Cell Fate Control
11.1.2 To Understand Cell Rejuvenation
11.1.3 To Understand Pluripotency
11.1.4 To Study Tissue & Organ Development
11.1.5 To Produce Human Gametes from iPSCs
11.1.6 Providers of iPSC-Related Services for Researchers
11.2 Applications of iPSCs in Drug Discovery
11.2.1 Drugs Tested for Cardiovascular Diseases using iPSCs
11.2.2 Drugs Tested for Neurological Diseases using iPSC Lines
11.2.3 Drugs Tested for Rare Diseases using iPSC Lines
11.3 Applications of iPSCs in Toxicology Studies
11.3.1 Examples of Drugs Tested for their Toxicity using iPSCs
11.3.2 Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
11.4 Applications of iPSCs in Disease Modeling
11.4.1 Cardiovascular Diseases Modeled with iPSC-Derived Cells
11.4.1.1 Percent Utilization of iPSCs for Cardiovascular Disease Modeling
11.4.2 Modeling Liver Diseases using iPSC-Derived Hepatocytes
11.4.3 iPSCs in Neurodegenerative Disease Modeling
11.4.4 iPSC-derived Organoids for Disease Modeling
11.4.5 Cancer-Derived iPSCs
11.5 Applications of iPSCs in Cell-Based Therapies
11.5.2 Companies Focusing only on iPSC-based Therapies
11.6 Other Novel Applications of iPSCs
11.6.1 Applications of iPSCs in Tissue Engineering
11.6.1.1 3D Bioprinting Techniques
11.6.1.2 Biomaterials
11.6.1.3 3D Bioprinting Strategies
11.6.1.4 Bioprinting iPSC-Derived Cells
11.6.2 iPSCs from Farm Animals
11.6.2.1 iPSCs Generated from Cattle
11.6.2.2 iPSCs from Sheep
11.6.2.3 iPSCs from Goat
11.6.2.4 iPSCs Generated from Buffalo
11.6.2.5 iPSC Generation from Avians
11.6.3 iPSC Lines for the Preservation of Endangered Species of Animals
11.6.4 iPSCs in Cultured Meat

12.1 Global Market for iPSCs by Geography
12.2 Global Market for iPSCs by Technology
12.3 Global Market for iPSCs by Biomedical Application
12.4 Global Market for iPSCs by Derived Cell Type
12.5 Market Drivers
12.5.1 Current Drivers Impacting the iPSC Market Place
12.6 Market Restraints
12.6.1 Economic Issues
12.6.2 Genomic Instability
12.6.3 Immunogenicity
12.6.4 Biobanking

13.1 AcceGen
13.1.1 ASC-CRISPR iPSC Gene Editing Technology Service
13.2 Acellta, Ltd
13.2.1 Technology
13.2.1.1 Maxells
13.2.1.2 Singles
13.2.1.3 Differentiation
13.2.1.4 Manufacturing Facility
13.2.1.5 Services
13.3 AddGene, Inc.
13.3.1 Viral Plasmids
13.4 Allele Biotechnology, Inc.
13.4.1 Technologies
13.4.1.1 mRNA Genome Editing
13.4.1.2 Single Cell Cloning
13.5 ALSTEM, Inc.
13.5.1 Cell Line Generation Tools
13.5.2 Cell Immortalization Kits
13.5.3 iPSC Kits
13.5.4 Cell Lines
13.5.5 Gene Editing
13.5.6 iPS Cell Lines
13.5.7 Virus Packaging Tools
13.6 Altos Labs
13.6.1 Altos’ Science
13.7 AMS Biotechnology, Ltd. (AMSBIO)
13.7.1 Cell Line Products
13.7.1.1 Disease Models
13.7.1.2 Viral Production Services
13.8 Applied StemCell (ASC)
13.8.1 iPSC-Based Preclinical CRO Services
13.8.1.1 Reprogramming to Differentiation
13.8.1.2 Neurotoxicity Screening
13.8.2 GMP Grade iPSC Services & Products
13.8.2.1 GMP iPSC
13.8.2.2 Knock-In Ready GMP TARGATT iPSCs
13.8.3 GMP TARGATT iPSC-iNK Platform
13.8.4 CRISPR iPSC Genome Editing Service
13.8.4.1 CRISPR Knock-In & Point Matation iPS Cell Generation
13.8.4.2 CRISPR iPSC Gene Knockout
13.8.4.3 TARGATT Knock-In iPS Cells
13.8.5 iPSC Generation Services
13.8.6 iPSC Differentiation Service
13.8.7 Stem Cell Products
13.9 Asgard Therapeutics
13.10 Aspen Neurosciences, Inc.
13.10.1 Aspen’s Clinical Pipeline
13.11 Astellas Pharma, Inc
13.11.1 Allogeneic Cell Therapy
13.11.2 Universal Donor Cell Technology
13.11.3 Astella’s Robust Pipeline
13.12 Axol Biosciences, Ltd
13.12.1 Axol’s Genetically Engineered Disease Lines
13.12.2 Custom Human iPSC iPSC Services
13.12.3 Axol’s Products
13.13 BioCentriq
13.13.1 LEAP Advanced Therapy Platform
13.14 Bit.bio
13.14.1 Therapeutics
13.14.2 Opti-Ox Reprogramming Technology
13.14.2.1 ioCells
13.14.2.2 ioWild Type Cells
13.14.2.3 ioGlutamatergic Neurons
13.14.2.4 ioSkeletal Myocytes
13.14.2.5 ioGABAergic Neurons
13.14.2.6 ioDisease Models
13.14.2.7 ioGlutamatergic Neurons50CAGWT
13.15 BlueRock Therapeutics LP
13.15.1 BlueRock’s Cell Therapy
13.15.2 CELL + GENE Platform
13.15.3 BlueRock’s Cell Therapy Programs
13.16 BrainXell
13.16.1 Products
13.16.2 Custom Service Projects
13.16.3 In-House Assay Services
13.17 Cartherics Pty, Ltd.
13.17.1 Allogeneic CAR Immune Cells
13.18 Catalent Biologics
13.18.1 OneBio Integrated Suite
13.18.2 Drug Substance Development
13.18.3 Drug Product Development
13.18.4 Analytical Services
13.18.5 Catalent’s iPSC Services
13.19 Cellistic
13.19.1 Pulse Platform
13.19.2 Echo Platform
13.19.3 iPSC-based Allogeneic Approach
13.19.3.1 Model 1
13.19.3.2 Model 2
13.20 CellOrigin Biotech (Hangzhou), Co., Ltd
13.21 Celogics, Inc.
13.21.1 Celo-Cardiomyocytes
13.22 Cellular Engineering Technologies (CET)
13.22.1 iPS Cell Reprogramming Methods
13.22.2 Applications of CET’s Stem Cells
13.22.2.1 Hypoimmune Cell Lines
13.22.2.2 Cell Therapy Development
13.22.2.3 Disease Modeling
13.22.2.4 Drug Development & Discovery
13.22.2.5 Regenerative Medicine
13.22.2.6 Toxicology Studies
13.22.3 Products
13.23 Cellusion, Inc.
13.23.1 Orphan Drug Designation
13.23.2 Bullous Keratopathy
13.24 Century Therapeutics, Inc
13.24.1 Cell Therapy Platform
13.24.2 Century’s Product Pipeline
13.25 Citius Pharmaceuticals, Inc.
13.25.1 Stem Cell Platform
13.26 Creative Bioarray
13.26.1 Pluripotent Stem Cells
13.26.2 iPSC-Derived Cells
13.26.3 Services
13.27 Curi Bio
13.27.1 Disease Model Development Services
13.28 Cynata Therapeutics, Ltd
13.28.1 Cymerus Platform
13.28.2 Clinical Development for GvHD
13.28.3 Osteoarthritis
13.28.4 ARDS
13.28.5 Diabetic Wounds
13.29 Cytovia Therapeutics
13.29.1 iPSC-derived NK & CAR-NK Cells
13.30 DefiniGEN
13.30.1 DefiniGEN’s Platform
13.30.2 Efficacy Screening Services
13.30.3 Toxicology Screening
13.30.4 Disease Models
13.30.5 iPSC Cell Products
13.31 Editas Medicine
13.31.1 SLEEK Gene Editing
13.31.2 iPSC-Derived NK Cells
13.32 Editco Bio., Inc.
13.32.1 Knockout iPS Cell Lines
13.32.2 Knock-in iPS Cell Lines
13.33 ElevateBio
13.33.1 iPSC Technology
13.34 Elixirgen Scientific, Inc
13.34.1 Technology
13.34.2 Service Offerings
13.34.3 iPSC Products
13.35 Eterna Therapeutics
13.35.1 Gene Editing
13.35.2 Gene Delivery
13.36 Evotec AG
13.36.1 iPS Cell Therapies
13.36.2 Drug Discovery Services
13.36.3 Therapeutic Areas
13.37 Eyestem
13.37.1 Eyecyte-RPE
13.37.2 Eyecyte-PRP
13.37.3 Aircyte-AEC
13.38 Fate Therapeutics
13.38.1 iPSC Platform
13.38.2 iPSC Manufacturing
13.38.3 Product Pipeline
13.38.3.1 FT576
13.38.3.2 FT522
13.38.3.3 FT819
13.38.3.4 FT825
13.38.4 Fate Therapeutics’ Collaborations
13.38.4.1 ONO Pharmaceutical, Co., Ltd.
13.38.4.2 Masonic Cancer Center, University of Minnesota
13.38.4.3 Memorial Sloan-Kettering Cancer Center
13.38.4.4 Oslo University Hospital
13.39 FUJIFILM Cellular Dynamics, Inc.
13.39.1 Products
13.39.2 FUJIFILM’s Custom Services
13.39.3 iPSC Disease Modeling
13.39.4 Safety Pharmacology/Toxicology Testing
13.40 Gameto
13.40.1 Fertilo
13.41 Greenstone Biosciences
13.42 Heartseed, Inc
13.42.1 HS-001: The Lead Product Candidate
13.42.2 Technologies
13.42.2.1 Remuscularization
13.42.2.2 Patented iPSC Production
13.42.2.3 Differentiation
13.42.2.4 Purification
13.42.2.5 Spheroid
13.43 HebeCell
13.43.1 ProtoNK
13.43.2 Retinal Photoreceptor Progenitors
13.43.3 Nanoproteins
13.44 Helios K.K.
13.44.1 Research Activities
13.45 Hera BioLabs
13.45.1 Proprietary SRG Rat
13.45.2 Cas-CLOVER Gene Editing Platform
13.45.3 The piggyback Transposon System Platform
13.45.4 Cell Line Development Services
13.45.5 Custom Cell Line Engineering Services
13.45.6 Animal Model Creation
13.45.7 In vivo Research Services
13.45.7.1 Custom Research Models
13.45.7.2 Metabolic Disease Models
13.45.7.3 Xenograft & PDX Services
13.45.7.4 Pharmacology & Toxicology Services
13.46 Hopstem Biotechnology
13.46.1 Pipeline
13.47 Implant Therapeutics, Inc.
13.47.1 Services
13.48 IN8bio
13.48.1 The DeltEx Platform
13.48.2 iPSC Gamma-Delta T Cells
13.49 I Peace, Inc.
13.49.1 GMP Products
13.49.2 Custom Manufacturing Services
13.50 IPS HEART
13.50.1 IPS HEART’s Approach
13.50.2 ISX-9 CPC
13.50.3 GIVI-MPC
13.51 iPS Portal, Inc.
13.51.1 Services
13.51.1.1 Development Services
13.51.1.2 Business Support Services
13.52 iPSirius
13.52.1 iPSirius’ Platform
13.53 iXCells Biotechnologies
13.53.1 iPS Cell Products
13.53.2 Preclinical Services
13.54 Kenai Therapeutics, Inc.
13.55 Khloris Biosciences, Inc
13.56 Kytopen
13.56.1 Products
13.56.1.1 Flowfect Discover
13.56.1.2 Flowfect TX
13.56.1.3 Flowfect Connect
13.57 Laverock Therapeutics
13.57.1 GEiGS and iPSCs
13.57.2 Ex Vivo GEiGS-Enabled Cell Therapies
13.58 Lindville Bio, Ltd
13.58.1 Services
13.59 Lonza Group, Ltd.
13.59.1 iPSC Manufacturing Expertise
13.59.2 Nucleofector Technology
13.60 Matricelf
13.60.1 Solution to Spinal Cord Injury
13.61 Megakaryon Corporation
13.61.1 Production of Platelets from iPSCs
13.61.2 Development of Megakaryocytes from iPSCs
13.61.3 Safe Production of Platelets
13.61.4 Research & Development Pipeline
13.62 Metrion Biosciences, Ltd
13.62.1 Ion Channel High-Throughput Screening
13.62.2 Clinical QTc/QRS Prediction using hiPSC-Derived Cardiomyocytes
13.63 Mogrify
13.63.1 MOGRIFY Platform
13.63.2 epiMOGRIFY Platform
13.64 Ncardia Services B.V
13.64.1 Ncyte Astrocytes
13.64.2 Ncyte Endothelial Cells
13.64.3 Ncyte Neural Mix
13.64.4 Ncyte Smooth Muscle Cells
13.64.5 Ncyte vCardiomyocytes
13.64.6 Custom Disease Modeling Services
13.64.7 High-Throughput Screening Services
13.64.8 iPSC-Based Efficacy Assay Services
13.64.9 iPSC-Based Safety & Toxicity Assays
13.65 NeuCyte
13.65.1 Technology
13.65.2 Drug Discovery
13.66 Neukio Biotherapeutics
13.66.1 Allogeneic Immunotherapy Platform
13.67 Newcells Biotech
13.67.1 Retina Models
13.67.2 Retinal Organoids
13.67.3 Retinal Pigment Epithelium (RPE)
13.67.4 Kidney Proximal Tubule Cell Model
13.67.5 Assay-Ready aProximate
13.67.6 Glomerular Toxicity and Disease Modeling
13.67.7 Lung Airway Models
13.67.8 Disease Modeling Services
13.67.8.1 In vitro Retinal Disease Modeling for Retinal Therapy
13.67.8.2 in vitro Evaluation of Retinal Toxicity Services
13.67.8.3 Gene Therapy Services
13.67.8.4 Drug Transporter Interactions & DDI Services
13.67.8.5 Cross Species Comparison Services
13.67.8.6 Kidney Toxicity Services
13.67.8.7 Kidney Disease Modeling Services
13.67.8.8 Fibroblast Assay Services
13.67.8.9 Lung Toxicity Study Services
13.68 NEXEL, Co., Ltd
13.68.1 Products
13.68.1.1 Cardiosight-S
13.68.1.2 Hepatosight-S
13.68.1.3 Neurosight-S
13.68.2 Curi Bio Systems
13.68.2.1 Mantarray
13.68.2.2 Cytostretcher
13.68.2.3 NanoSurface Plates
13.68.3 Services
13.68.3.1 NeXST (Next Xight Screening Test)
13.68.3.2 Curi Engine SVC
13.69 Notch Therapeutics
13.69.1 Technology
13.69.2 Product Development
13.70 Orizuru Therapeutics, Inc.
13.70.1 iCM Project
13.71 Phenocell SAS
13.71.1 iPSC-derived RPE Cells for Age-related Macular Degeneration (AMD)
13.71.2 R&D Solutions for Acne & Hyperseborrhea
13.71.3 Skin Pigmentation Research & Testing Platform
13.71.4 Cells & Kits
13.72 Pluristyx
13.72.1 The panCELLa Platform
13.72.2 RTD iPSC & GMP Cell Banks
13.72.3 Development Services
13.72.4 Custom Gene Editing
13.72.5 iPSC GMP Manufacturing Expertise
13.72.6 Custom Gene Editing
13.72.7 FailSafe
13.72.8 iACT Stealth Cells
13.72.9 Products
13.72.9.1 PluriBank PSCs
13.72.9.2 ESI Pluripotent Stem Cells
13.72.9.3 Wild Type & Disease Affected PSCs
13.72.10 Differentiated Cells
13.73 ReNeuron
13.73.1 Technology Platform
13.74 Repairon GmbH
13.74.1 Technology
13.74.1.1 Engineered Heart Muscle (EHM)
13.75 REPROCELL USA, Inc
13.75.1 Services
13.75.1.1 Donor Recruitment and Patient-Derived Cells
13.75.1.2 Example Case Study
13.75.1.3 Target Cell Isolation
13.75.1.4 iPSC Reprograming Service
13.75.1.5 iPSC Expansion, Characterization and Banking Services
13.75.1.6 Neuronal Differentiation Services
13.75.1.7 Gene Editing Services
13.75.2 REPROCELL’s iPSC Products
13.75.2.1 Stemgent
13.76 Res Nova Bio, Inc.
13.76.1 Preclinical Study
13.77 Sartorius CellGenix GmbH
13.77.1 Products
13.78 Shinobi Therapeutics
13.79 Shoreline Biosciences
13.79.1 iMACs
13.80 StemSight
13.80.1 Technology
13.81 Stemson Therapeutics
13.81.1 iPSCs for Hair Follicles
13.82 Stemina Biomarker Discovery
13.82.1 Cardio quickPREDICT
13.82.2 devTOX quickPREDICT
13.83 Tempo Bioscience, Inc
13.83.1 Tempo-iAstro
13.83.2 Tempo-iBMEC
13.83.3 Tempo-iCardio
13.83.4 Tempo-iCort
13.83.5 Tempo-iDopaNer
13.83.6 Tempo-iLSEC
13.83.7 Tempo-iKupffer
13.83.8 Tempo-iHepStellate
13.83.9 Tempo-iHep3D
13.83.10 Tempo-iKer
13.83.11 Tempo-iKidneyPod
13.83.12 Tempo-iMel
13.83.13 Tempo-iMG
13.83.14 Tempo-iMono
13.83.15 Tempo-iMotorNer
13.83.16 Tempo-iMSC
13.83.17 Tempo-iNStem
13.83.18 Tempo-iOligo
13.83.19 Tempo-iOsteo
13.83.20 Tempo-iPeri
13.83.21 Tempo-iPhago
13.83.22 Tempo-iRPE
13.83.23 Tempo-iSchwann
13.83.24 Tempo-iSenso
13.83.25 Tempo StemBank
13.84 Uncommon (Higher Steaks)
13.84.1 iPSC-Based Cultured Pork
13.85 Universal Cells
13.85.1 Technologies
13.85.1.1 Recombinant Adeno-Associated Virus
13.85.1.2 PSCs for Every Organ
13.85.1.3 Universal Donor Cells
13.85.1.4 HLA Engineering
13.86 VCCT, Inc.
13.86.1 Regenerating RPE Cells
13.87 ViaCyte, Inc
13.87.1 Technology
13.87.1.1 Autologous Approach
13.87.1.2 Allogeneic Approach
13.87.2 Pipeline
13.88 Vita Therapeutics
13.88.1 Technology
13.89 XCell Science
13.89.1 Control Lines
13.89.1.1 XCL-1
13.89.1.2 XCL-6
13.89.2 Cell Products
13.89.2.1 Control Lines
13.89.2.2 Knock-out Lines
13.89.2.3 Reporter Lines
13.89.3 Services
13.90 Yashraj Biotechnology, Ltd.
13.90.1 iPSC Products
13.90.2 Contract Research Services

FIGURE 3.1: Development of iPSC-based Autologous Cell Therapy for Canavan Disease
FIGURE 3.2: Manufacturing Timeline for Autologous iPSC-derived Cell Products
FIGURE 3.3: Cost of iPSC Production
FIGURE 3.4: Technical Set Up of the Stem Cell Factory (SCF)
FIGURE 3.5: Development of iPSC-based Allogeneic Cell Therapy
FIGURE 3.6: Share of iPSC-based Research within the Overall Stem Cell Industry
FIGURE 3.7: Major Focus Areas of iPSC Companies
FIGURE 3.8: Relative use of iPSC-derived Cell Types in Toxicology Studies
FIGURE 3.9: Comparison of Lipofection and Nucleofection Technologies
FIGURE 5.1: No. of Research Publications on iPSC in PubMed.gov, 2010-May 29, 2024
FIGURE 5.2: Pubmed Publications on Pathophysiological Research using iPSCs
FIGURE 5.3: PubMed Publications on Reprogramming Somatic Cells
FIGURE 5.4: No. of PubMed Papers on iPSC Differentiation
FIGURE 5.5: PubMed Papers on the use of iPSCs in Drug Discovery
FIGURE 5.6: PubMed Papers on iPSC-based Cell Therapy
FIGURE 5.7: Percent Share of Published Articles by Disease Type
FIGURE 5.8: Percent Share of Articles by Country
FIGURE 6.1: Number of iPSC Patents Filed by Year, 2000-May 5, 2024
FIGURE 7.1: Number of Clinical Trials by Year
FIGURE 7.2: iPSC Clinical Trials by Design, May 2024
FIGURE 7.3: Therapeutic & Non-Therapeutic iPSC Clinical Trials
FIGURE 7.4: Non-Therapeutic Clinical Trials by Use
FIGURE 7.5: Percent Share of Diseases Targeted by Therapeutic Studies
FIGURE 7.6: Share of Autologous & Allogeneic iPSCs in Clinical Studies
FIGURE 7.7: iPSC Clinical Trials by Phase of Study
FIGURE 7.8: iPSC Clinical Trials by Funder Type
FIGURE 9.1: The Roles of OSKM Factors in the Induction of iPSCs
FIGURE 9.2: Delivery Methods for iPSC Induction
FIGURE 9.3: Schematic of Retroviral Delivery Method
FIGURE 9.4: Schematic of Lentiviral Delivery Method
FIGURE 9.5: Schematic of piggyBack Transposon Delivery Method
FIGURE 9.6: Shematic of Adenoviral Vector Delivery
FIGURE 9.7: oriP/Epstein-Barr Nuclear Antigen-1 (EBNA1)-based Episomes
FIGURE 9.8: RNA Delivery Approach
FIGURE 9.9: Protein Delivery
FIGURE 10.1: PubMed Citations for iPSCs and iPSC Lines registered in hPSCreg
FIGURE 10.1: Disease States represented by NIGMS Cell Lines
FIGURE 10.2: Subject Age Range in Collections
FIGURE 11.1: Biomedical Applications of iPSCs
FIGURE 11.1: Advantages of iPSC usage in Drug Discovery
FIGURE 11.2: iPSCs and their Potential for Toxicity Testing and Drug Screening
FIGURE 11.3: Relative Use of iPSC-Derived Cell Types used in Toxicity Testing Studies
FIGURE 11.4: Percent Share Utilization of iPSCs for Cardiovascular Disease Modeling
FIGURE 11.5: Techniques used for iPSC Bioprinting
FIGURE 12.1: Estimated Global Market for iPSCs by Geography, 2023-2030
FIGURE 12.2: Estimated Global Market for iPSCs by Technology, 2023-2030
FIGURE 12.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030
FIGURE 12.4: Global Market for iPSCs by Derived Cell Type, 2023
FIGURE 13.1: dCas9-VPR System
FIGURE 13.2: Universal Donor Cell Technology
FIGURE 13.3: Century’s Approach to iPSC Therapy
FIGURE 13.4: FT576
FIGURE 13.5: FT522
FIGURE 13.6: FT819
FIGURE 13.7: FT825
FIGURE 13.8: Developing iPSC Neurons by SynFire Technology
FIGURE 13.9: Mantarray Instrument
FIGURE 13.10: Cytostretcher
FIGURE 13.11: NanoSurface Plate
FIGURE 13.12: Repairon’s Engineered Heart Muscle (EHM)
FIGURE 13.13: REPROCELL’s Example Case Study: Alzheimer’s Disese
FIGURE 13.14: Cardio quickPREDICT Process
FIGURE 13.15: devTOX quickPREDICT Process

TABLE 3.1: Examples of Autologous iPSC-derived Cell Therapies in Development
TABLE 3.2: Examples of Clinical Trials involving Allogeneic iPSCs
TABLE 3.3: Commercially Available iPSC-derived Cell Types
TABLE 3.4: iPSC-derived Cell Types used in Clinical Trials
TABLE 4.1: Timeline of Important Milestones Reached in iPSC Industry
TABLE 5.1: No. of Research Publications on iPSC in PubMed.gov, 2006-June 1, 2024
TABLE 6.1: iPSC Patent Applications by Jurisdiction as of May 5, 2024
TABLE 6.2: Patent Applicants as of May 5, 2024
TABLE 6.3: iPSC Patent Inventors
TABLE 6.4: iPSC Patent Owners
TABLE 6.5: Legal Status of iPSC Patents
TABLE 7.1: Recruitment Status of iPSC Clinical Trials, May 2, 2024
TABLE 7.2: Examples of iPSC-based Therapeutic Interventional Studies
TABLE 7.3: The Promising iPSC-based Product Candidates Developed across the World
TABLE 7.4: Examples of Key iPSC-based Preclinical Studies
TABLE 8.1: M&A in iPSC Sector
TABLE 8.2: Partnership/Collaboration & Licensing Deals in iPSC Sector, 2021-May 2024
TABLE 8.3: Venture Capital Funding in iPSC Sector, 2021-May 2024
TABLE 9.1: Pluripotency-Associated Transcription Factors and their Functions
TABLE 9.2: Diffewrent Combinations of Factors for Different Cell Sources
TABLE 9.3: Comparison of Delivery Methods of Reprogramming Factors
TABLE 9.4: iPSC Disease Models Generated by CRISPR/Cas9
TABLE 9.5: Available iPSC lines and their Major Applications
TABLE 10.1: Major Biobanks Storing iPSCs & iPSC Lines
TABLE 10.2: Disease-Specific iPSCs offered by RIKEN
TABLE 10.3: Types of iPS Cell Lines available with WiCell - a Sample
TABLE 10.4: The Four California Institutions recruiting Tissue Donors
TABLE 10.5: iPSC Disease Samples with FCDI
TABLE 10.6: Examples of Allen’s Fluorescently Tagged hiPSC lines
TABLE 10.7: Rett Syndrome Trust’s iPSC Collection
TABLE 10.8: Cell Sources & Reprogramming Methods for iPSC Banks
TABLE 10.9: Ownership of iPSC Banks and the Investments Made
TABLE 11.1: Providers of iPSC-Related Services and Products for Researchers
TABLE 11.2: Drugs Tested for Cardiovascular Diseases using iPSCs
TABLE 11.3: Drugs Tested for Neurological Diseases using iPSC Lines
TABLE 11.4: Drugs Tested for Rare Diseases using iPSC Lines
TABLE 11.5: Examples of Drugs Tested for their Toxicity using iPSC-Derved Cell Lines
TABLE 11.6: Published Human iPSC Models
TABLE 11.7: Partial List of Cardiovascular & other Diseases Modeled using iPSCs
TABLE 11.8: Liver Diseases Modeled using iPSCs
TABLE 11.9: Examples of iPSC-Based Neurodegenerative Diseae Modeling
TABLE 11.10: Organoid Types and Diseae Modeling Applications
TABLE 11.11: Examples of Cancer-Derived iPSCs
TABLE 11.12: Major Sponsors of iPSC-based Cell Therapies
TABLE 11.13: Selected Interventional Clinical Trials of iPSC-Based Cell Therapy
TABLE 11.14: Companies focusing only on iPSC-based Therapies
TABLE 11.15: Features of Different iPSC Bioprinting Techniques
TABLE 11.16: Bioprinting of iPSC-Derived Cells
TABLE 11.17: iPSCs Generation from Cattle
TABLE 11.18: iPSCs Generation from Sheep
TABLE 11.19: iPSCs Generation from Goat
TABLE 11.20: iPSCs Generation from Buffalo
TABLE 11.21: iPSC Generation from Avians
TABLE 11.22: Timeline of Development of iPSCs Generated from Domestic & Wild Animals
TABLE 12.1: Estimated Global Market for iPSCs by Geography, 2023-2030
TABLE 12.2: Estimated Global Market for iPSCs by Technology, 2023-2030
TABLE 12.3: Estimated Global Market for iPSCs by Biomedical Application, 2023-2030
TABLE 12.4: Global Market for iPSCs by Derived Cell Type, 2023-2030
TABLE 13.1: Aspen’s Clinical Pipeline
TABLE 13.2: Astella’s Robust & Competitive Pipeline
TABLE 13.3: Bit.bio’s Cell Therapy Pipeline
TABLE 13.4: BlueRock’s Pipeline of Cell Therapy Products
TABLE 13.5: Cartheric’s R&D Pipeline
TABLE 13.6: CellOrigin’s R&D Pipeline
TABLE 13.7: Cellusion’s Pipeline
TABLE 13.8: Century’s Pipeline Products
TABLE 13.9: Cytovia’s iPSC-Derived CAR-iNK Product Pipeline
TABLE 13.10: Eterna’s R&D Pipeline
TABLE 13.11: Eyestem’s Product Pipeline
TABLE 13.12: Fate Therapeutic’s Product Pipeline
TABLE 13.13: Examples of Greenstone’s iPSC Line Collections
TABLE 13.14: HebeCell’s Product Pipeline
TABLE 13.15: Helio’s Research & Development Status
TABLE 13.16: Hopstem’s Product Pipeline
TABLE 13.17: IPS HEART’s R&D Pipeline
TABLE 13.18: iPSirius’ R&D Pipeline
TABLE 13.19: Kenai Therapeutic’s Pipeline
TABLE 13.20: Khloris Biosciences’ iPSC-Based Clinical Programs
TABLE 13.21: Laverock’s R&D Pipeline
TABLE 13.22: Megakaryon’s Research & Development Pipeline
TABLE 13.23: NEXEL Pipeline
TABLE 13.24: Notch Therapeutic’s R&D Pipeline
TABLE 13.25: Available Stemgent iPSCs with REPROCELL
TABLE 13.26: Shinobi Therapeutics’ Product Pipeline
TABLE 13.27: ViaCyte’s Product Pipeline
TABLE 13.28: Vita Therapeutic’s R&D Pipeline